Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Rimoldi

Showing results (51-60 of 69) with videos related to

Pageof 7
Sort By:
International Journal of Cancer|August 19, 1993
Human melanoma cells express a functional interleukin-2 receptorS Plaisance, E Rubinstein, A Alileche, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 20, 1998
Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analoguesD Valmori, J F Fonteneau, C M Lizana, et al.
European Journal of Cancer (Oxford, England : 1990)|August 26, 1998
Reliability of reverse transcription-polymerase chain reaction (RT-PCR)-based assays for the detection of circulating tumour cells: a quality-assurance initiative of the EORTC Melanoma Cooperative GroupU Keilholz, M Willhauck, D Rimoldi, et al.
The Journal of Experimental Medicine|September 28, 1999
In vivo expression of natural killer cell inhibitory receptors by human melanoma-specific cytolytic T lymphocytesD E Speiser, M J Pittet, D Valmori, et al.
The Journal of Experimental Medicine|November 6, 1998
Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytesP Romero, P R Dunbar, D Valmori, et al.
International Journal of Cancer|August 14, 1999
cDNA and protein characterization of human MAGE-10D Rimoldi, S Salvi, D Reed, et al.
Science (New York, N.Y.)|November 22, 1996
Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escapeM Hahne, D Rimoldi, M Schröter, et al.
The Journal of Experimental Medicine|December 6, 2000
Cross-priming of naive CD8 T cells against melanoma antigens using dendritic cells loaded with killed allogeneic melanoma cellsF Berard, P Blanco, J Davoust, et al.
Cancer Research|September 2, 2000
Naturally occurring human lymphocyte antigen-A2 restricted CD8+ T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patientsD Valmori, V Dutoit, D Liénard, et al.
International Immunology|December 11, 1999
Optimal activation of tumor-reactive T cells by selected antigenic peptide analoguesD Valmori, J F Fonteneau, S Valitutti, et al.
Pageof 7

Showing results (51-60 of 69) with videos related to

Sort By:
Pageof 7
International Journal of Cancer|August 19, 1993
Human melanoma cells express a functional interleukin-2 receptorS Plaisance, E Rubinstein, A Alileche, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 20, 1998
Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analoguesD Valmori, J F Fonteneau, C M Lizana, et al.
European Journal of Cancer (Oxford, England : 1990)|August 26, 1998
Reliability of reverse transcription-polymerase chain reaction (RT-PCR)-based assays for the detection of circulating tumour cells: a quality-assurance initiative of the EORTC Melanoma Cooperative GroupU Keilholz, M Willhauck, D Rimoldi, et al.
The Journal of Experimental Medicine|September 28, 1999
In vivo expression of natural killer cell inhibitory receptors by human melanoma-specific cytolytic T lymphocytesD E Speiser, M J Pittet, D Valmori, et al.
The Journal of Experimental Medicine|November 6, 1998
Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytesP Romero, P R Dunbar, D Valmori, et al.
International Journal of Cancer|August 14, 1999
cDNA and protein characterization of human MAGE-10D Rimoldi, S Salvi, D Reed, et al.
Science (New York, N.Y.)|November 22, 1996
Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escapeM Hahne, D Rimoldi, M Schröter, et al.
The Journal of Experimental Medicine|December 6, 2000
Cross-priming of naive CD8 T cells against melanoma antigens using dendritic cells loaded with killed allogeneic melanoma cellsF Berard, P Blanco, J Davoust, et al.
Cancer Research|September 2, 2000
Naturally occurring human lymphocyte antigen-A2 restricted CD8+ T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patientsD Valmori, V Dutoit, D Liénard, et al.
International Immunology|December 11, 1999
Optimal activation of tumor-reactive T cells by selected antigenic peptide analoguesD Valmori, J F Fonteneau, S Valitutti, et al.
Pageof 7